Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia

Inclusion Criteria: * A definite diagnosis of acute DILI; * 5×ULN ≤ TBIL level at baseline ≤ 20×ULN; * Age 18-80 years old; * Sign the informed consent form. Exclusion Criteria: * Other causes of liver injury, including viral hepatitis, cytomegalovirus infection, Epstein-Barr virus infection, Herpes virus infection, autoimmune liver disease, alcoholic liver disease, hypoxic/ischemic liver disease, Budd-Chiari syndrome, biliary tract disease, Wilson's disease, hemochromatosis, and α1-antitrypsin deficiency; * Immune checkpoint inhibitors or gynura segetum induced DILI; * Absolute contraindications to glucocorticoids, such as systemic mold infections or allergies; * A history of glucocorticoid therapy within 3 months before enrollment; * A history of diseases requiring glucocorticoid maintenance therapy, such as rheumatoid arthritis, systemic lupus erythematosus, systemic dermatomyositis, etc; * A history of liver transplantation; * Received artificial liver therapy before enrollment; * Malignant tumor of the liver, bile duct, pancreas or liver metastasis * Acute liver failure; * Renal dysfunction, creatinine Cr≥133μmol/L; * Neutrophil count \<1,000,000,000/L; * Active tuberculosis; * Severe cardiopulmonary diseases; * Recent surgery or trauma; * Mental illness; * Pregnancy or lactation; * Participated in other clinical studies within 3 months before enrollment; * Other conditions judged by the clinician to be inappropriate for study participation.